Journal of Pediatric Biochemistry 2015; 05(04): 157-160
DOI: 10.1055/s-0036-1572422
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Role of Alfa Fetoprotein in the Risk Management of Pediatric Germ Cell Tumors

Carla Moscheo
1   Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
,
Andrea Di Cataldo
2   Department of Clinical and Experimental Medicine, Unit of Paediatric Haematology and Oncology, Policlinico “G. Rodolico” Hospital, University of Catania, Catania, Italy
,
Filippo Spreafico
1   Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
,
Stefano Chiaravalli
1   Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
,
Serena Catania
1   Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
,
Monica Terenziani
1   Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
› Author Affiliations
Further Information

Publication History

14 December 2015

23 December 2015

Publication Date:
09 February 2016 (online)

Abstract

Germ cell tumors (GCTs) are a rare group of neoplasms that arise from pluripotent stem cells. They display variable behavior depending on age, histology, primary tumor site, and stage of disease. In pediatric GCTs serum alfa fetoprotein (AFP) is the most frequently used marker for diagnosis and monitoring, although it is not specific only for these diseases. In this review, we discuss extracranial GCTs and the usefulness of AFP in their management.

 
  • References

  • 1 Khanna S, Arya NC, Gupta IM, Gupta S, Singhal GD. Germ cell tumors in Indian children. J Surg Oncol 1988; 37 (4) 235-238
  • 2 Steliarova-Foucher E, Stiller C, Kaatsch P , et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 2004; 364 (9451) 2097-2105
  • 3 Malati T. Clinical relevance of AFP, its molecular variants and HCG in hepatoblastoma and childhood germ cell tumors. Clin Biochem 2014; 47 (9) 734
  • 4 Billmire DF. Malignant germ cell tumors in childhood. Semin Pediatr Surg 2006; 15 (1) 30-36
  • 5 Terenziani M, D'Angelo P, Inserra A , et al. Mature and immature teratoma: a report from the second Italian pediatric study. Pediatr Blood Cancer 2015; 62 (7) 1202-1208
  • 6 Shu XO, Nesbit ME, Buckley JD, Krailo MD, Robinson LL. An exploratory analysis of risk factors for childhood malignant germ-cell tumors: report from the Childrens Cancer Group (Canada, United States). Cancer Causes Control 1995; 6 (3) 187-198
  • 7 Chen Z, Stewart PA, Davies S , et al. Parental occupational exposure to pesticides and childhood germ-cell tumors. Am J Epidemiol 2005; 162 (9) 858-867
  • 8 Rutgers JL, Scully RE. Pathology of the testis in intersex syndromes. Semin Diagn Pathol 1987; 4 (4) 275-291
  • 9 Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 1987; 25 (2) 191-218
  • 10 Schneider DT, Terenziani M, Cecchetto G, Olson TA. Gonadal and extragonadal germ cell tumors, sex cord stromal and rare gonadal tumors. In: Schneider DT, Brecht IB, Olson TA, Ferrari A, eds. Rare Tumors in Children and Adolescents, Pediatric Oncology. Berlin, Heidelberg: Springer; 2012: 327-402
  • 11 Perlman EJ, Hawkins EP. Pediatric germ cell tumors: protocol update for pathologists. Pediatr Dev Pathol 1998; 1 (4) 328-335
  • 12 Schneider DT, Calaminus G, Göbel U. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. Pediatr Hematol Oncol 2001; 18 (1) 11-26
  • 13 Ohama K, Nagase H, Ogino K , et al. Alpha-fetoprotein (AFP) levels in normal children. Eur J Pediatr Surg 1997; 7 (5) 267-269
  • 14 Blohm ME, Vesterling-Hörner D, Calaminus G, Göbel U. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol 1998; 15 (2) 135-142
  • 15 Marina N, Fontanesi J, Kun L , et al. Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 1992; 70 (10) 2568-2575
  • 16 Mann JR, Raafat F, Robinson K , et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18 (22) 3809-3818
  • 17 Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T. Significance of elevated preoperative α-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors. J Surg Oncol 2006; 94 (7) 619-623
  • 18 Frazier AL, Rumcheva P, Olson T , et al; Children's Oncology Group. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 50 (4) 746-751
  • 19 Baranzelli MC, Kramar A, Bouffet E , et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 1999; 17 (4) 1212
  • 20 Marina N, London WB, Frazier AL , et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006; 24 (16) 2544-2548
  • 21 Frazier AL, Hale JP, Rodriguez-Galindo C , et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 2015; 33 (2) 195-201
  • 22 Olson TA, Murray MJ, Rodriguez-Galindo C , et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol 2015; 33 (27) 3018-3028
  • 23 Brodeur GM, Howarth CB, Pratt CB, Caces J, Hustu HO. Malignant germ cell tumors in 57 children and adolescents. Cancer 1981; 48 (8) 1890-1898
  • 24 Billmire D, Vinocur C, Rescorla F , et al; Children's Oncology Group (COG). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39 (3) 424-429 , discussion 424–429
  • 25 Rescorla FJ. Pediatric germ cell tumors. Semin Surg Oncol 1999; 16 (2) 144-158
  • 26 Göbel U, Calaminus G, Engert J , et al. Teratomas in infancy and childhood. Med Pediatr Oncol 1998; 31 (1) 8-15
  • 27 Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 1976; 37 (5) 2359-2372
  • 28 Sarin YK, Bhatnagar SN. Extracranial malignant germ cell tumors. Indian J Pediatr 2012; 79 (7) 928-935
  • 29 Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50 (18) 5904-5910
  • 30 Lee DJ, Djaladat H, Tadros NN , et al. Growing teratoma syndrome: clinical and radiographic characteristics. Int J Urol 2014; 21 (9) 905-908
  • 31 Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 1982; 50 (8) 1629-1635
  • 32 Gorbatiy V, Spiess PE, Pisters LL. The growing teratoma syndrome: current review of the literature. Indian J Urol 2009; 25 (2) 186-189
  • 33 De Corti F, Sarnacki S, Patte C , et al. Prognosis of malignant sacrococcygeal germ cell tumours according to their natural history and surgical management. Surg Oncol 2012; 21 (2) e31-e37